VLDLR and chronic kidney disease: In animal studies, metabolic dysregulation mediated by CKD resulted in enhanced lipolysis and lipid mobilization with fat redistribution from the adipose tissue to the liver mediated by zinc a2-glycoprotein, which up-regulates perlipin and lipoprotein lipase and down-regulates the VLDL receptor [80,94].